Tacrolimus 0.1% is a topical calcineurin inhibitor used as a non‑steroidal anti‑inflammatory treatment for moderate‑to‑severe atopic dermatitis and sensitive areas where steroid‑sparring is desired, by blocking calcineurin–NFAT signaling to reduce T‑cell cytokines and itch without causing skin atrophy. Off‑label, it is commonly employed for localized vitiligo and intertriginous or facial psoriasis, often complemented with phototherapy or occlusion on select sites to enhance repigmentation or control inflammation. Routine guidance includes consistent application, sun‑protective habits during therapy, and dermatology follow‑up for response assessment.